Pfizer Basic Shares Outstanding 2010-2024 | PFE
Pfizer annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Pfizer basic shares outstanding for the quarter ending September 30, 2024 were $5.667B, a 0.37% increase year-over-year.
- Pfizer basic shares outstanding for the twelve months ending September 30, 2024 were $22.633B, a 0.44% increase year-over-year.
- Pfizer annual basic shares outstanding for 2023 were $5.643B, a 0.62% increase from 2022.
- Pfizer annual basic shares outstanding for 2022 were $5.608B, a 0.12% increase from 2021.
- Pfizer annual basic shares outstanding for 2021 were $5.601B, a 0.83% increase from 2020.
Pfizer Annual Basic Shares Outstanding
(Millions of US $) |
| 2023 |
$5,643 |
| 2022 |
$5,608 |
| 2021 |
$5,601 |
| 2020 |
$5,555 |
| 2019 |
$5,569 |
| 2018 |
$5,872 |
| 2017 |
$5,970 |
| 2016 |
$6,089 |
| 2015 |
$6,176 |
| 2014 |
$6,346 |
| 2013 |
$6,813 |
| 2012 |
$7,442 |
| 2011 |
$7,817 |
| 2010 |
$8,036 |
| 2009 |
$7,007 |
Pfizer Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2024-09-30 |
$5,667 |
| 2024-06-30 |
$5,666 |
| 2024-03-31 |
$5,657 |
| 2023-12-31 |
$5,643 |
| 2023-09-30 |
$5,646 |
| 2023-06-30 |
$5,646 |
| 2023-03-31 |
$5,634 |
| 2022-12-31 |
$5,608 |
| 2022-09-30 |
$5,607 |
| 2022-06-30 |
$5,593 |
| 2022-03-31 |
$5,617 |
| 2021-12-31 |
$5,601 |
| 2021-09-30 |
$5,609 |
| 2021-06-30 |
$5,598 |
| 2021-03-31 |
$5,584 |
| 2020-12-31 |
$5,555 |
| 2020-09-30 |
$5,557 |
| 2020-06-30 |
$5,554 |
| 2020-03-31 |
$5,545 |
| 2019-12-31 |
$5,569 |
| 2019-09-30 |
$5,545 |
| 2019-06-30 |
$5,562 |
| 2019-03-31 |
$5,635 |
| 2018-12-31 |
$5,872 |
| 2018-09-30 |
$5,875 |
| 2018-06-30 |
$5,866 |
| 2018-03-31 |
$5,957 |
| 2017-12-31 |
$5,970 |
| 2017-09-30 |
$5,951 |
| 2017-06-30 |
$5,958 |
| 2017-03-31 |
$6,006 |
| 2016-12-31 |
$6,089 |
| 2016-09-30 |
$6,066 |
| 2016-06-30 |
$6,068 |
| 2016-03-31 |
$6,150 |
| 2015-12-31 |
$6,176 |
| 2015-09-30 |
$6,168 |
| 2015-06-30 |
$6,159 |
| 2015-03-31 |
$6,203 |
| 2014-12-31 |
$6,346 |
| 2014-09-30 |
$6,330 |
| 2014-06-30 |
$6,368 |
| 2014-03-31 |
$6,389 |
| 2013-12-31 |
$6,813 |
| 2013-09-30 |
$6,581 |
| 2013-06-30 |
$7,042 |
| 2013-03-31 |
$7,187 |
| 2012-12-31 |
$7,442 |
| 2012-09-30 |
$7,436 |
| 2012-06-30 |
$7,476 |
| 2012-03-31 |
$7,537 |
| 2011-12-31 |
$7,817 |
| 2011-09-30 |
$7,770 |
| 2011-06-30 |
$7,875 |
| 2011-03-31 |
$7,982 |
| 2010-12-31 |
$8,036 |
| 2010-09-30 |
$8,027 |
| 2010-06-30 |
$8,046 |
| 2010-03-31 |
$8,061 |
| 2009-12-31 |
$7,007 |
| 2009-09-30 |
$6,730 |
| 2009-06-30 |
$6,728 |
| 2009-03-31 |
$6,723 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.305B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
